Abstract
The discorvery of oncogenic driver has uncovered the pathogenesis of non-small cell lung cancer (NSCLC), and development of corresponding kinase inhibitors has changed treatment strategies and improved survival of patients with druggable oncogenic drivers. However, such oncogenic drivers are not found in 25-40% of lung adenocarcinoma, the most common histological subtype of NSCLC. We established in 2013 a multi-institutional lung cancer genome screening platform, LC-SCRUM-Asia, to identify lung cancer with oncogenic drivers, and to clinically develop molecular targeted therapies.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
